ICU Medical, Inc.

ICU Medical, Inc.

ICUIยทNASDAQ

$130.52

+0.21%
HealthcareMedical - Instruments & Supplies

ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy and critical care applications worldwide. The company's infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; SwabCap and SwabTip disinfecting caps; Tego hemodialysis connectors; ClearGuard HD, an antimicrobial barrier cap for hemodialysis catheters; and ChemoClave and ChemoLock closed system transfer devices, as well as Diana hazardous drug compounding system for the preparation of hazardous drugs. It also provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation comprising sodium chloride and sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. The company offers infusion pumps under the Plum 360 and LifeCare PCA brands; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform that connects smart pumps to hospital's electronic health records, asset tracking systems, and alarm notification platforms; and related professional services. It also provides critical care products, such as Cogent 2-in-1 and CardioFlo hemodynamic monitoring systems; TDQ and OptiQ cardiac output monitoring catheters; TriOx venous oximetry catheters; Transpac blood pressure transducers; and SafeSet closed blood sampling and conservation systems. The company sells its products to acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, including outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is headquartered in San Clemente, California.

At a Glance

Live Snapshot
Market Cap$3.26B
EPS0.0297
P/E Ratio4394.61
Earnings Date08/06/2026

Intrinsic Alpha Methodology

Thesis Lenses

Signal ยท Driver ยท Risk

Signal

High confidence

Valuation multiple is elevated (P/E 4394.6).

Valuation inputs: P/E 4394.6, earnings yield +0.0%, momentum +0.2%.

If multiples stay elevated while momentum fades, downside repricing risk rises.

Driver

High confidence

Return profile is soft (ROE +0.0%, ROIC +0.7%).

Profitability stack: net margin +0.0%, ROE +0.0%, ROIC +0.7%.

Quality deterioration often appears in margins before it shows up in headline EPS.

Risk

High confidence

Risk profile is balanced but has notable pressure points to monitor.

Risk factors: liabilities/assets +47.6%, momentum +0.2%, net margin +0.0%.

Higher leverage with weak momentum and thin margins can amplify drawdown severity.

icui

ICU Medical, Inc. Market vs Earnings Trajectory

ICUI ยท NASDAQ

Loading price and EPS data...

ICU Medical, Inc.

ICU Medical, Inc. Fair Value Envelope

ICUI ยท NASDAQ

Our analysis suggests that ICUI has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $130.52, this represents a potential HIDDEN relative to our calculated worth for ICU Medical, Inc..

Intrinsic Value
Current Price: $130.52
3Y-101.0%
5Y-99.0%
10Y-99.0%
3Y-2.0%
5Y+75.0%
10Y+488.0%
3Y-101.0%
5Y-99.0%
10Y-99.0%
3Y-389.0%
5Y-19.0%
10Y+100.0%
3Y-157.0%
5Y-25.0%
10Y+40.0%
3Y-10.0%
5Y+130.0%
10Y+475.0%
ICU Medical, Inc.

ICU Medical, Inc. Profit Bridge

ICUI ยท NASDAQ
Revenue2.23B
Cost of Goods Sold (1.41B)
Gross Profit819.65M
Operating Expenses (712.71M)
Operating Income106.95M
Interest Expense (105.38M)
Other Income/Expense-103.78M
Pretax Income3.17M
Income Tax (2.44M)
Net Income732.00K
Net Income
732.00K

Profitability Analysis

Gross Margin

36.8%

Strong gross margins indicate healthy pricing and efficient production or service delivery.

Operating Margin

4.8%

Minimal operating profit suggests high operating costs or pricing challenges. Scalability is concerning.

Net Profit Margin

0.0%

Minimal profitability after all expenses. Limited financial flexibility for reinvestment or shareholder returns.

Effective Tax Rate

76.9%

Higher tax burden may reflect limited tax optimization or operations in high-tax jurisdictions.

Profitability Insight

Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.

36.76%
Gross Profit Margin
6%
3Y+20.0%
5Y+1.0%
10Y-31.0%
4.80%
Operating Profit Margin
166%
3Y-355.0%
5Y-38.0%
10Y-78.0%
0.03%
Net Profit Margin
-101%
3Y-101.0%
5Y-100.0%
10Y-100.0%
0.03%
Return on Equity
-101%
3Y-101.0%
5Y-99.0%
10Y-100.0%
0.02%
Return on Assets
-101%
3Y-101.0%
5Y-100.0%
10Y-100.0%
0.69%
Return on Invested Capital
-40%
3Y-201.0%
5Y-88.0%
10Y-93.0%
ICUI

ICU Medical, Inc. Cash Conversion Engine

ICUI ยท NASDAQ
Net Income732.00K
Depreciation & Amortization200.74M
Stock-Based Compensation55.76M
Change in Working Capital-90.04M
Others12.66M
Capital Expenditures-88.04M
Free Cash Flow91.80M

Cash Flow Quality Analysis

FCF Conversion Rate

12541.5%

Excellent cash generation. The company converts earnings to cash at or above 100%, indicating high-quality earnings.

CapEx Intensity

49.0%

Capital-intensive operations require significant reinvestment. Monitor whether CapEx is maintenance or growth-oriented.

FCF Growth Trend

-26.4%

Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.

Working Capital Impact

-$90.04M

Significant working capital drain. Growth may be consuming cash through inventory buildup or receivables extensionโ€”monitor closely.

Cash Flow Quality Insight

Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.

icui

ICU Medical, Inc. Funding & Solvency Profile

ICUI ยท NASDAQ
Cash & Cash Equivalents288.33M
Net Receivables201.08M
Inventory605.59M
Other Current Assets118.25M
Total Current Assets1 B
Property, Plant & Equipment495.93M
Goodwill & Intangible Assets2.08B
Long-Term Investments130.92M
Other Non-Current Assets63.50M
Total Non-Current Assets690 M
Total Assets
4.01B

Financial Health Analysis

Current Ratio

2.34x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.90x

Balanced capital structure with moderate leverage. Equity exceeds debt, suggesting healthy financial stability.

Working Capital

695 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

30% Current

Capital-intensive business with significant long-term investments in property, equipment, or intangibles.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

icui

ICU Medical, Inc. Street Expectations Map

ICUI ยท NASDAQ

Wall Street analysts project that ICUI stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 164.00, with estimates ranging from a low of 163.00 to a high of 165.00.

Lowest Target
163.00
24.89%
Consensus Target
164.00
25.65%
Highest Target
165.00
26.42%

The consensus 1-year price target stands at 164.00, with estimates ranging from a low of 163.00 to a high of 165.00.

Analyst Consensus Analysis

Upside Potential

+25.6%

Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.

Analyst Agreement

1.2% spread

High analyst agreement. Narrow target range indicates strong consensus on valuation, suggesting clear investment thesis and predictable outlook.

Analyst Conviction

Very High

Strong buy conviction: High upside with tight consensus suggests compelling investment opportunity backed by analyst confidence.

Market Sentiment Insight

Rare opportunity: Exceptional upside potential with strong analyst consensus creates a compelling setup. The combination of significant price target premium and tight agreement suggests high-conviction undervaluation that may attract institutional capital.

icui

ICU Medical, Inc. Insider Positioning

ICUI ยท NASDAQ

During the last 12 months, insiders have purchased $343K and sold $1.64M worth of ICUI shares, resulting in $1.29M of net selling activity.

3 Months

Bought

0

0.00

Sold

7.0K

882.24K

Net Activity

-882K

-$882K

3-6 Months

Bought

0

0.00

Sold

0

0.00

Net Activity

+0

+$0

6-9 Months

Bought

0

0.00

Sold

5.1K

754.18K

Net Activity

-754K

-$754K

9-12 Months

Bought

3.0K

342.55K

Sold

0

0.00

Net Activity

+343K

+$343K

Top Buyers

1
JV

Jain Vivek

Director, Officer: Chairman And Ceo

2.4K sharesโ€ข1 transactions

$267K

2
GDC

Greenberg David C.

Director

602 sharesโ€ข1 transactions

$76K

Top Sellers

1
WD

Woolson Daniel

Officer: President

5.0K sharesโ€ข2 transactions

$722K

2
SVR

Sanzone Virginia Ruth

Officer: Vp, General Counsel

3.4K sharesโ€ข2 transactions

$436K

3
GDC

Greenberg David C.

Director

2.4K sharesโ€ข1 transactions

$298K

4
FEW

Finney Elisha W

Director

1.3K sharesโ€ข1 transactions

$180K

Insider Activity Analysis

Net Insider Sentiment

Bearish

Strong bearish signal with $1.29M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.

Buy/Sell Ratio

0.21:1

Weak buy/sell ratio. Selling significantly exceeds buyingโ€”monitor for potential fundamental concerns.

Recent Trend (3 Months)

$882K

Heavy recent selling activity. Recent insider sales notably exceed purchasesโ€”may warrant investigation into company developments.

Insider Participation

Moderate Selling

4 insider sellers vs. 2 buyers. More insiders selling than buying suggests cautious or negative sentiment.

Insider Activity Insight

Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.

0.00%
Dividend Yield
3Y-
5Y-
10Y-
ย 

icui Dividend History

ICUI
10Y CAGR +0%
Latest $0
Annual $0
Stable dividend payments
Last Period: +0%